San Diego, USA, 2018-12-11 - NBE-Therapeutics was invited to present at KNect365's 2018 Antibody Engineering & Therapeutics Conference
Roger Beerli, CSO of NBE-Therapeutics, was invited to provide an update on NBE-Therapeutics' ADC development activities at KNect365's 2018 Antibody Engineering & Therapeutics Conference in San Diego, USA.
NBE-Therapeutics was invited for a presentation at KNect365's 2018 Antibody Engineering & Therapeutics Conference. Roger's presentation took place in the "Meeting Challenges for Antibody Therapies in the Tumor Microenvironment" stream on Tuesday, Dec 11, 3:30 p.m. and was entitled "Preclinical Validation of a Site-specifically Conjugated, ROR1-specific Anthracycline-ADC with Potent Immunestimulatory Functions". Roger's presentation included data demonstrating a strong immune-stimulatory function of NBE's anthracycline-based ADC platform that can trigger a long-lasting anti-tumor immunity in syngeneic mouse tumor models.
Recent news feed
RSS feed from: